Neihulizumab  (Synonyms: ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab))

Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Humanized

Neihulizumab is a monoclonal antibody against P-selectin glycoprotein ligand-1 (PSGL-1). Neihulizumab binds to human PSGL-1, thereby preferentially inducing apoptosis in late stage activated T cells. At sites of inflammation, the endothelium of blood vessels expresses P-selectin, and activated T cells bind to these sites and migrate through the expression of PSGL-1. In that manner, Neihulizumab is thought to target activated T cells and inhibit trafficking to sites of inflamed tissue^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145720.00

2158362-38-8

Liquid

Colorless to light yellow

[Neihulizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized CD162/PSGL-1 Protein, Human (HEK293, His, HY-P77163) can bind Neihulizumab. The EC₅₀ for this effect is 2.298 ng/mL.

• [1]. Sameem Abedin, et al. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease. J Exp Pharmacol. 2020 Nov 26;12:549-557.  [Content Brief]

  [2]. Sameem Abedin, et al. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD). Blood (2022) 140 (Supplement 1): 10495-10497.